Deep Life Medical develops advanced medical devices and phytopharmaceutical solutions to address major unmet medical needs, including sickle cell disease, osteoarthritis, and respiratory validation.
Deep Life Medical has two divsions: medical device engineering where we develop implanted or invasive medical devices, and phyto-nutraceuticals division where we apply advanced analytical techniques to identify active compounds in African herbal remedies.
African Bitter Root Supplement™ has been used for millenia by those with diseases involving pathologies in which cell membranes becoming stiff and lose the lipids needed for flexibility.
Order Learn More
Advanced respiratory simulator for automated validation of ventilators, rebreathers and other respiratory systems.
Download datasheet
A SPARK Ada program for managing blinded clinical trials to GCP, EU Annex 11, and 21 CFR Part 11 regulations. CT Manager operates double and triple blinded clinical trial protocols in a manner which preserves blinding of investigators and sponsors, while decisions for dose escalation, pause, stopping or adaption are transparent and auditable.
Learn moreCT Manager is a SIL3+ validated SPARK Ada program that runs blinded trial protocols. It allows investigators to enter data, while the program makes the decisions in Phase dose escalation trials, and Phase 2+3 Efficacy+Safety trials, while keeping the blinding secure. The program is designed to meet 21 CRF Part 11 & EU GCP Annex 11, providing full audit logs, emergency unblinding, and regulatory reporting.
The traditional African supplement used by people with osteoarthritis and sickle cell disease is now available as a food supplement in the UK and Europe.
In partnership with Open Safety Equipment Ltd, our latest respiratory simulator provides rapid, automated testing of key ventilator parameters.
Randomised trial on 110 patients showed Anugel significantly reduces the need for post-surgical analgesics. Product progressing toward certification.
LRQA has renewed Deep Life Medical’s certifications in the UK and Portugal, with zero non-conformances identified.